A1AT, alpha-1-antitrypsin; AATD, alpha-1-antitrypsin deficiency; AUC, area under curve; B3gnt2, UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2; Cas9, CRISPR-associated protein 9; C1INH, C1 esterase inhibitor; CHO, Chinese hamster ovary; CRISPR, clustered regularly interspaced short palindromic repeats; FACS, fluorescence-activated cell sorting; FITC, Fluorescein isothiocyanate; Fut8, alpha-(1,6)-fucosyltransferase; Glul, glutamate-ammonia ligase; HAE, hereditary angioedema; HM, high-mannose; indel, insertion or deletion; IVC, integral of viable cells; KO, knock-out; mAb, monoclonal antibody; Mgat4A, mannosyl (alpha-1,3-)-glycoprotein beta-1,4-Nacetylglucosaminyltransferase isozyme A; Mgat4B, mannosyl (alpha-1,3-)glycoprotein beta-1,4-N-acetylglucosaminyltransferase isozyme B; Mgat5, mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetylglucosaminyltransferase; MSX, methionine sulfoximine; sgRNA, single guide RNA; SNA, sambucus nigra agglutinin; Sppl3, signal peptide peptidase like 3; St3gal3, ST3 beta-galactoside alpha-2,3-sialyltransferase 3; St3gal4, ST3 beta-galactoside alpha-2,3-sialyltransferase 4; St3gal6, ST3 beta-galactoside alpha-2,3-sialyltransferase 6; ST6GAL1, ST6 beta-galactoside alpha-2,6-sialyltransferase 1; VCD, viable cell density; WT, wild type Abstract Recombinant Chinese hamster ovary (CHO) cells are able to provide biopharmaceuticals that are essentially free of human viruses and have N-glycosylation profiles similar, but not identical, to humans. Due to differences in N-glycan moieties, two members of the serpin superfamily, alpha-1-antitrypsin (A1AT) and plasma protease C1 inhibitor (C1INH), are currently derived from human plasma for treating A1AT and C1INH deficiency.
Here, we present engineered CHO cell lines producing rhA1AT or rhC1INH with fully humanized N-glycosylation profiles. This was achieved by combining CRISPR/Cas9mediated disruption of 10 gene targets with overexpression of human ST6GAL1. We were able to show that the N-linked glyco-structures of rhA1AT and rhC1INH are homogeneous and similar to the structures obtained from plasma-derived A1AT and C1INH, marketed as Prolastin ® -C and Cinryze ® , respectively. rhA1AT and rhC1INH produced in our glycoengineered cell line showed no detectable differences to their plasma-purified counterparts on SDS-PAGE and had similar enzymatic in vitro activity. The work presented here shows the potential of expanding the glyco-engineering toolbox for CHO cells to produce a wider variety of glycoproteins with fully humanized N-glycan profiles. We envision replacing plasma-derived A1AT and C1INH with recombinant versions and thereby decreasing our dependence on human donor blood, a limited and possibly unsafe protein source for patients.
Introduction
Chinese hamster ovary (CHO) cells serve an important role in the biotechnology industry as the primary workhorse for the production of recombinant protein therapeutics [1] .
Many of these therapeutics are glycoproteins that contain one or more N-glycan and/or Oglycan chains. As N-glycans can potentially affect protein folding, immune regulation, cellular homeostasis and the biological half-life of proteins [2, 3] , it is considered a critical quality attribute and much effort has been put forth to improve features of protein Nglycosylation. The production of diverse N-glycan structures is a major contributor to the heterogeneity of protein products derived from CHO cells. The inherent heterogeneity of CHO N-glycan profiles is especially a drawback when one distinct N-glycan structure is desired on the protein product. Two examples of human plasma proteins with distinct, homogeneous N-glycan structures are found within the serpin superfamily, alpha-1-antitrypsin (A1AT) and C1 esterase inhibitor (C1INH) [4] . Patients with the genetic disorders alpha-1-antitrypsin deficiency (AATD) or hereditary angioedema (HAE-C1INH) have decreased plasma levels of functional A1AT or C1INH, respectively, and are currently treated with prophylactic augmentation therapy of plasma purified A1AT or C1INH [5, 6] .
Augmentation therapy is cost intensive [5] , and C1INH purified from pooled donor plasma has been associated with hepatitis C virus infections prior to the introduction of virucidal methods [7] . Despite current dedicated virus inactivation steps, cases of Hepatitis G transmission have been reported [8] and non-enveloped viruses can still be transmitted via plasma-derived products [9] . Nevertheless, approved C1INH formulas are concentrates purified from human donors (Berinert ® , Cinryze) despite containing undesired protein impurities identified as α1-antichymotrypsin, ceruloplasmin and Factor C3 [6] .
Both native human plasma A1AT (plA1AT) and C1INH (plC1INH) possess a N-glycan profile with ~60-80% diantennary, disialylated, non-fucosylated (A2G2S2) structures with human-like alpha-2,6-linked sialic acids. plA1AT has three N-glycosylation sites [4] , where natural A2G2S2 structures are not essential for biological activity but enhance in vivo half-life and in vitro protein stability [10, 11] . plC1INH is thought to be one of the most heavily glycosylated plasma proteins and harbors ten O-linked and six N-linked glycan structures [12] . The six N-linked glycan moieties with A2G2S2 as predominant structure have been shown to be increase serum half-life and are reported to increase in vivo efficacy [13] [14] [15] .
The ability to generate high A2G2S2 N-glycan proportions on rhA1AT/rhC1INH may be critical for improving product quality. Although efforts have been reported, generating high proportions of A2G2S2 N-glycans has not to our knowledge been published. For instance, CHO cells lack active St6 beta galactoside alpha-2,6-sialyltransferase 1 (ST6GAL1) to cap N-glycans with alpha-2,6-linked sialic acids [16] . rhA1AT and rhC1INH
were produced in various platforms [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . However, these approaches revealed low productivity or the N-glycosylation was far from the profile of plA1AT or plC1INH and therefore cleared rapidly from the human blood making intravenous administration impractical.
Commercially available rhC1INH from transgenic rabbits shows activity similar to plC1INH and has decreased virus transmission risk. However, it differs in N-glycosylation profiles from plC1INH and therefore reveals a risk of allergy, a dissatisfactory pharmacokinetic profile and consequently is unlikely to be of use in prophylaxis [30] .
Glycosylation-engineering in primary human cells aimed to mimic O-glycan profiles of plC1INH. However, complete sialylation of rhC1INH N-glycan structures was not achieved [31] .
To address this, we aimed to engineer the heterogeneous CHO-S N-glycan profile towards a predominantly non-fucosylated biantennary A2G2 structure by combining the publicly available CHO-K1 genome sequence [32] , clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9) for multiplexing gene editing [33] , and reported CHO glycosyltransferases [34] ,. To this end, we made functional knockouts of the Glul-gene and nine glycosylation-gene targets (10x KO, Suppl. Table 1 ).
We hypothesized that rhA1AT and rhC1INH produced in this genetic background with parallel co-expression of ST6GAL1 would display an N-glycan profile similar to plA1AT and plC1INH with predominant A2G2S2 N-glycan structures. We present CHO clones producing rhA1AT/rhC1INH similar to plA1AT/plC1INH when assessed by N-glycan analysis, protein activity, SDS-PAGE and isoelectric focusing. CHO derived rhA1AT and rhC1INH with fully humanized N-glycan profiles have the potential to replace the costintensive and possibly unsafe plasma-based augmentation therapy of AATD and HAE-C1INH patients without compromising activity and N-glycosylation.
Materials and methods

sgRNA, GFP_2A_Cas9 and A1AT/C1INH_ST6GAL1_Glul plasmid design
GFP_2A_Cas9 and single guide RNA (sgRNA) plasmids were constructed as previously described [33] . The sgRNA target design for Mgat4A, Mgat4B, Mgat5, St3gal3, St3gal4, St3gal6, B3gnt2, Fut8, Sppl3 and Glul was performed using "CRISPy" [35] . The target sites for the mentioned genes and the oligos for sgRNA cloning are listed in Suppl. Table S1 and Table S2 , respectively.
Plasmids for co-expression of A1AT/C1INH and ST6GAL1 were constructed with uracilspecific excision reagent cloning method as previously described [36, 37] (Suppl. Fig. 1 ).
The DNA sequences of the plasmids are listed in Suppl. Table S5 .
Cell cultivation and transfection for genome editing
CHO-S suspension cells were incubated in a humidified incubator at 120 rpm, 37°C, 5%
CO2, passaged to 2-3 x 10 5 cells/mL every 2-3 days and transfected in 6-well plates (BD Biosciences, San Jose, CA) as described previously [33] . The GFP_2A_Cas9 / sgRNA plasmid ratios for each transfection was 1:1 of which the plasmid load of sgRNA was divided equally by the amount of different sgRNAs used per transfection (Suppl . Table S4 ). To measure FACS sorting efficiency, pmaxGFP ® vector (Lonza, Basel, Switzerland) transfection was performed as well. Cells were harvested for fluorescence-activated cell sorting (FACS) 48 h post transfection.
Single cell cloning of genome edited cells using FACS
Prior to FACS, cells were filtered through a 40 μm cell strainer into a FACS-compatible tube.
Single fluorescent-positive (GFP) cells were sorted into 384-well plates (Corning, New York, NY) containing 30 μL CD CHO medium supplemented with 8 mM L-glutamine, 1.5%
HEPES buffer and 1% Antibiotic-Antimycotic (Gibco, Waltham, MA) per well as described previously [38] . For cell sorting, fluorescent-positive cell populations were gated based on non-transfected WT CHO-S cells. Two weeks after cell sorting cell colonies were moved to 96-well flat-bottom plates (BD Biosciences) and expanded for deep sequencing analysis and batch cultivation. [33] . PCR primers are presented in Suppl. Table S3 .
Deep sequencing analysis
Transfection and expression in polyclonal cell lines by applying MSX-selection
Cells were seeded in 250 mL Corning vent cap shake flasks (Sigma-Aldrich) as duplicates with cell densities ~1 x 10 6 cells/mL in 60 mL CD CHO medium supplemented with 8 mM L-glutamine (Life Technologies) and transfected with 75 μg of A1AT-Glul-ST6GAL1 plasmid or 75 μg of C1INH-Glul-ST6GAL1 plasmid (Suppl. Fig. 1 
Single cell cloning of cells from polyclonal cell pools using FACS
Non-stained single cells were sorted from pools as described above. For cell sorting, all viable cells were gated for sorting into 384-well plates with L-glutamine-free medium.
Two weeks after cell sorting the clones were moved to 96-well flat-bottom plates (BD Biosciences) and expanded to shake flask format in CD CHO medium supplemented with 1μL/mL anti-clumping agent, 25 μM MSX and lacking L-glutamine. 
Screening cell pools and single cell clones for human-like α-2,6-sialic acid linkage formation with lectin staining
Batch cultivation: cell growth analysis and N-glycosylation profiling
Titer assessment of rhA1AT/rhC1INH producing clones
rhA1AT and rhC1INH titers were determined using biolayer interferometry on an Octet RED96 (Pall, Menlo Park, CA, USA) as described previously for A1AT [39] . Assays were performed in 96-well black microplates (Greiner Bio-One, Kremsmünster, Austria). Octet System Data Analysis 7.1 software was used to calculate binding rates and absolute A1AT and C1INH concentrations.
SDS-PAGE, isoelectric focusing and PNGase treatment
SDS-PAGE was performed on Novex 4-12% Tris-Glycine mini gels and isoelectric focusing (IEF) was performed on Novex pH 3-10 IEF gels (Thermo Fisher Scientific) as per the manufacturer's instructions. Deglycosylation with PNGase F was performed according to the manufacturer's instructions (New England Biolabs, Ipswich, MA). Emission: 530 nm, slit width 13.5 nm).
Activity assays
C1INH inhibitory activity was determined using the Technochrom C1INH Assay Kit (TechnoClone, Vienna, Austria). In short, plasma containing C1INH activity (120%, 60%, 30%) and samples (~0.25 µM) were incubated with substrate-buffer mixture for 3 min at room temperature, after which 50% acetic acid was added. Extinction was measured at 405 nm.
N-Glycan analysis
N-glycans were derivatized with GlycoWorks RapiFluor-MS N-Glycan Kit (Waters, Milford, MA) according to the manufacturer's instruction. Briefly; 12 μg purified protein or 12 μl of 10x concentrated (Amicon Ultra-15, Merck) secretome sample was used for each sample.
Labeled N-Glycans were analyzed by LC-MS as described previously [33] . Separation gradient from 30% to 43% 50 mM ammonium formate buffer and MS were run in positive mode. Amount of N-Glycan was measured by integrating the peaks with Thermo Xcalibur software (Thermo Fisher Scientific, Waltham, MA) giving the normalized, relative amount of the glycans.
Proteomics
Preparation of protein extract from CHO cells were done as previously described in Bonde et al., 2016 [40] . Liquid chromatography was performed on a Cap-LC system (Thermo scientific) coupled to an 75 µm x 15 cm 2µm C18 easy spray column (Thermo Scientific).
The flow rate 1.2 ul and using a stepped gradient, going from 4% to 40% acetonitrile water over 50 minutes. The samples were sprayed into an Orbitrap Q Exactive HF-X mass spectrometer (Thermo Scientific). MS-level scans with resolution set to 60,000; Data dependent MS2 selection with HCD collision energy set to 28%. The resulting data were analyzed using MaxQuant. Data was searched against the Chinese hamster database retrieved from Uniprot with proteome Id UP000001075.
Results
Growth profile and N-glycan profile of clonal 10x KO cell lines
The aim of our study was to produce rhA1AT and rhC1INH in CHO cells with N-glycan profiles similar to human plA1AT and plC1INH. Our approach was to engineer the heterogeneous N-glycan profile of CHO-S WT cells towards a homogeneous A2G2S2 Nglycan structure, which is the predominant N-glycan on plA1AT/plC1INH. To this end, we generated out-of-frame insertions or deletions (indels) in eight glycosyltransferase genes (Mgat4A, Mgat4B, Mgat5, St3gal3, St3gal4, St3gal6, B3gnt2, Fut8) as well as in the genes Sppl3 and Glul (Suppl . Table S4 ) over four successive rounds of multiplexed CRISPR/Cas9 gene editing. Two clones with indels in the targeted genes were subjected to growth analysis and N-glycan profiling.
Two clones (10x KO A and 10x KO B) with out-of-frame indels in all ten gene targets were obtained and both showed a pronounced increase in batch culture longevity when compared to the parental CHO-S WT cell line ( Fig. 1A ). After disruption of the targeted genes, the proportion of A2G2 within N-glycan structures of total secreted proteins was increased from 3.5% (CHO-S WT) to 79% in both 10x KO clones (Fig. 1C ). We concluded that the 10x KO A and B clones were suitable host cell lines in our effort to generate humanized N-glycans.
Introducing human-like sialylation in 10x KO cell lines
On the basis of A2G2 secretome N-glycan structures of clone 10x KO B, we aimed to develop clonal cell lines expressing ST6GAL1 and rhC1INH or ST6GAL1 and rhA1AT. We envisioned that such cell lines are capable to produce rhA1AT or rhC1INH with predominant A2G2S2 N-glycan structures as found on plA1AT and plC1INH. The functional
Glul-KO selection system was confirmed by MSX-dosage dependent recovery times of cell viabilities from transfected cell pools (Suppl. Fig. 3A) . Passaging of the different transfection pools was performed until viability and doubling times were stable. We then conducted FACS-based single cell cloning with the 50 μM MSX-selected cells. During the expansion of the generated clones, only clones exhibiting predominant FITC-SNA staining and detectable levels of rhA1AT/rhC1INH in supernatants on coomassie-stained SDS-PAGE gels were selected (Suppl. Fig. 2 ). Based on these criteria, two rhA1AT (A1-1 and A1-2) and two rhC1INH (C1-1 and C1-2) producing clones were selected for further characterization.
SNA lectins are reported to bind predominantly to sialic acids of N-glycans linked to the galactose residue in a human-like alpha-2,6-sialylation. Analyzing FITC-SNA-stained CHO-S WT, we found relatively low levels of alpha-2,6-sialylation ( Fig. 2A ). To determine the proportion of cells with human-like sialylation, FITC-SNA stained CHO-S WT samples were used to gate between FITC-positive and FITC-negative cells (Suppl. Fig. 2A ). Within the two 50 μM MSX-selected polyclonal cell lines, <30% of the cells were found to comprise alpha-2,6-linked sialic acids on N-glycans of cell surface proteins (Fig. 2B ). In comparison, 82-90% of the cells in the populations of the selected four clones (A1-1, A1-2, C1-1 and C1-2) had the desired alpha-2,6-linked sialic acids on their N-glycans. 
Extended culture longevity retained in rhA1AT and rhC1INH-producing clones
Both the two rhA1AT-and the two rhC1INH-producing clones showed the extended culture longevity as well as maximum VCD similar to the parental 10x KO B cell line (Fig.   3A ). Viabilities of all clones were >75% until day 9 and clone C1-2 maintained cell viability >75% until day 11, similar to the non-producing parental 10x KO B.
In both rCh1INH-producing clones, rhC1INH titers increased from day 0 until day 5, but then stagnated at ~40 μg/mL until the end of the batch cultures ( Fig. 3B ). In comparison, SDS-PAGE gel analysis revealed that purified rhA1AT and rhC1INH produced in the four clones seem to have hydrodynamic volumes (molecular weight) similar to plA1AT and plC1INH without detectable impurities as seen in plC1INH (Fig. 4A ). rhA1AT and rhC1INH produced in CHO-S WT background did not co-migrate with plA1AT and plC1INH, respectively. However, after deglycosylation with PNGaseF, all recombinantly produced proteins aligned with corresponding bands of plA1AT and plC1INH with the exception of rhC1INH produced in a CHO-S WT background displayed an additional protein band at ~65 kDa. In vitro activity assessment of plC1INH and rhC1INH purified from clones C1-1 and C1-2. As described in the assay, 1 IU/ml C1INH activity was set to 100%. Error bars indicate range of duplicate measurements.
To further characterize the CHO-produced rhA1AT and rhC1INH, we performed IEF gel analysis ( Fig. 4B ). rhA1AT from clones A1-1 and A1-2 manifested in two bands with isoelectric points (pI) at ~ pH 4.5 similar to plA1AT. In contrast, rhA1AT produced in a CHO-S WT background displayed more than nine detectable isoforms with pI between pH 4 -5.
IEF gel analysis of rhC1INH produced in a CHO-S WT background resulted in isoforms with pI ranging from pH ~4 -5.5. A high degree of heterogeneity was also found in purified rhC1INH produced in clone C1-1. However, rhC1INH produced in clone C1-2 was less heterogeneous with pI at pH ~3.5 similar to plC1INH.
In N-glycan analysis of purified rhA1AT and rhC1INH from CHO-S WT cells we detected a higher degree of heterogeneity compared to N-glycan structures on rhA1AT and rhC1INH from polyclonal 10x KO cell pools (Suppl. Fig. 3B ). The polyclonal cell lines revealed two predominant sugar structures on both proteins (A2G2 and A2G2S2 N-glycans), whereas we could not detect the A2G2S2 structure on products from CHO-S WT. Moreover, the amount of predominant N-glycan structures on rhA1AT and rhC1INH was decreased from two (polyclonal pools) to one (monoclonal producers), identified as A2G2S2 N-glycan ( Fig.   4C ).
All four 10x KO-derived monoclonal cell lines produced rhA1AT and rhC1INH with higher proportion of A2G2S2 structures than plA1AT and plC1INH (Suppl. Fig. 2C and Suppl. Fig.   3C ). The proportion of A2G2S2 in rhA1AT and rhC1INH was approximately 88 -92% and 84%, respectively, and 82% for plA1AT and 66% for plC1INH .
Finally, we investigated the activity of purified rhA1AT and rhC1INH. rhA1AT activity was determined by its inhibitory function of elastase activity (Fig. 4D, Suppl. Fig. 4B ). Similar to plA1AT and rhA1AT from CHO-S WT, a decrease in elastase activity was detected at A1AT concentrations >0.1 μM for rhA1AT from clones A1-1 and A1-2. In addition, 50% of elastase inhibition was reached at ~0.3 μM A1AT for plA1AT as well as rhA1AT. In vitro activity of purified rhC1INH produced by clones C1-1 and C1-2 was similar or higher compared to plC1INH.
Discussion
We aimed to produce rhA1AT and rhC1INH in CHO-S with N-glycan profiles similar to plA1AT and plC1INH, which to our knowledge has not yet been achieved by recombinant expression. First, the heterogeneous N-glycan profile of CHO-S WT cells was changed to more homogeneous profiles in bespoke cell lines with predominant A2G2 N-glycan structures (Fig. 1B) . Disrupting nine N-glycosylation-related genes increased the A2G2 proportion on total secreted protein from 3.5% in CHO-S WT-derived cells to ~80% in 10x KO cell lines (Fig. 1C) . This supports the previously suggested strategy to decrease Nglycan branching and alpha-2,3-sialylation by disrupting Mgat4A, Mgat4B, Mgat5, St3gal3, St3gal4 and St3gal6 [34] . The impact of gene disruptions on cell culture performance was assessed in batch cultures. Interestingly, the monoclonal cell lines with disruption in ten gene targets showed enhanced growth characteristics compared to CHO-S WT cells (Fig.   1A ). Overexpression of the Glul gene has previously been found to decrease ammonia levels, which might explain improved CHO cell growth of the four characterized producer clones in L-glutamine-free medium [39] . However, the cause for the boosted cell growth of Glul-lacking 10x KO cell lines in L-glutamine-supplemented medium (Fig. 1A) remains to be explored in further studies. Additionally, when CHO-S cells are subjected to a single cell sorting-based selection procedure, we suspect that the protocol generates monoclonal cell lines with an extended culture longevity phenotype compared to the parental cell line.
Thus, we do not suggest that knocking out the 10 gene targets lead to the observed extended culture longevity phenotype.
Since the disruption of the ten targets did not seem to interfere with cell culture performance, we performed co-expression of ST6GAL1 and rhA1AT or ST6GAL1 and rhC1INH in the 10x KO-derived clone B. After transfection, we observed a MSXconcentration dependent recovery of the transfected cell pools and successful killing of untransfected 10x KO B after 5 days of growth in L-glutamine-free medium similar to a previous study (Suppl. Fig. 3A ) [41] . However, untransfected CHO-S WT cells were also able to recover up to the highest MSX-concentration of 50 μM, which is in accordance to previous work [36] . As shown in the killing curve of the untransfected 10x KO cells, the advantage of the Glul-KO system here seems to be the elimination of untransfected cells.
Surprisingly, after selection at 50 μM MSX, the polyclonal cell lines did not show the desired predominant A2G2S2 glycosylation of purified rhA1AT and rhC1INH as we found incomplete sialylation on both proteins (Suppl. Fig. 3B ). Similar lack of sialylation in the polyclonal cell lines was found after FITC-SNA lectin staining where only <30% of cells were identified to have alpha-2,6-sialylation (Fig. 2B ). This might be due to incomplete vector integration into the genomic DNA or chromosome instability leading to a heterogeneous cell population with reduced stability of the integrated elements as reported earlier [42] . The cell pools most likely harbor a mixture of cells which do not all express the ST6GAL1-protein successfully. However, we were able to discard clones with incomplete sialylation by single cell cloning and screening for FITC-SNA lectin positive clones producing rhA1AT or rhC1INH.
Although the stagnating rhC1INH titer at day 5, the reported rhC1INH titer here is higher than previously reported production platforms with maximum titers of only 6 μg/mL in insect cells [29] and 30 μg/mL in P. pastoris [27] albeit the media we used was without any optimization for protein production. Further investigation needs to be carried out to understand the stagnation of rhC1INH titers. However, it can be speculated that the rate of rhC1INH production is similar to the rate of rhC1INH degradation, preventing an increase of rhC1INH titer in the cultivation supernatant.
In comparison to plC1INH (Cinryze), the rhC1INH from C1-1 and C1-2 did not show α1antichymotrypsin, ceruloplasmin and Factor C3 impurities on SDS-PAGE gels [8] (Fig. 4A) ,
implying that CHO-based cell platforms possibly can supply HAE-C1INH patients with higher purity than human plasma.
With titers between 300 -400 μg/mL, human neuronal cell lines produce rhA1AT with higher titers than our clones A1-1 and A1-2. However, rhA1AT from these neuronal cells exhibits core-fucosylation, is not fully sialylated, and therefore differs largely from plA1AT N-glycosylation [24] . Similarly, earlier studies expressed rhA1AT in CHO with titers of up to 1.15 g/L, though differing from plA1AT by revealing core-fucosylation and alpha-2,3sialylation [25, 26, 43] .
In contrast to the production platforms listed earlier, rhA1AT and rhC1INH produced in our 10x KO cell lines are not only exceeding sialylation levels of plA1AT and plC1INH (Suppl. Fig. 2C ), but also reveal human-like alpha-2,6-sialylation instead of alpha-2,3sialylation. Previous work reported only 2.6% A2G2S2 structures on rhA1AT expressed in CHO-K1, however with 2,3-sialic-acid linkage [26] .
Interestingly, the increased sialylation of rhA1AT from the two clones had no impact on in vitro activity (Fig. 4D ). This is in accordance with previous work, which showed that A1AT activity is not linked to its N-glycosylation and CHO WT produced rhA1AT has similar activity to plA1AT [10, 38] . Furthermore, differences of CHO-S WT-and 10x KO-derived rhA1AT were made visible using IEF gel analysis, where rhA1AT from the two clones revealed similar patterns to plA1AT (Fig. 4B ).
As presented in Fig. 4B , in contrast to rhA1AT, rhC1INH differed partially in IEF gel analysis profile from plC1INH. Increased rhC1INH sialylation (Suppl. Fig. 2C ) might lead to altered charge distribution and consequently cause changes in IEF gel patterns. For rhC1INH from clone C1-1, we observed a double-band in SDS-PAGE analysis although Nglycans were removed by PNGaseF treatment (Fig. 4A ). This might indicate that O-glycan charge variants are responsible for the heterogeneity observed in IEF gel analysis and SDS-PAGE of rhC1INH from C1-1 ( Fig. 4A and 4B ) as described previously [44] .
In summary, our work describes a strategy to successfully engineer the heterogeneous Nglycosylation profile of CHO-S WT cells to the specific A2G2S2 N-glycan structure with the purpose of producing rhA1AT and rhC1INH with N-glycan profiles similar to human plasma-derived products. We used CRISPR/Cas9 to disrupt ten genes and then overexpressed rhA1AT or rhC1INH on a ST6GAL1-and Glul-encoding plasmid. After selection with MSX and single cell cloning, we identified clones expressing rhA1AT or rhC1INH with titers of up to 124 μg/mL and 42 μg/mL, respectively (Fig. 3B) . Purified rhA1AT and rhC1INH were similar to the plasma-derived counterparts judged by SDS-PAGE analysis (Fig. 4A ), degree and type of sialylation (Fig. 2B, Suppl. Fig. 2C, Suppl. Fig.   3C ) and in vitro activity (Fig. 4D) . Thus, the work presented shows the promise and potential of replacing cost-intensive and possibly unsafe plasma-derived augmentation therapy for AATD and C1INH-HAE patients by CHO-produced rhA1AT and rhC1INH. This strategy is in compliance with the Medical and Scientific Advisory Council (MASAC) recommendation of replacing plasma-derived products with recombinant products for treatment of diseases [45] .
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Suppl. Fig. 1  2 Suppl. Fig. 2  3 Suppl. Fig. 3  4 Suppl. Fig. 4 5 Table S1  6   Table S2  7   Table S3  8   Table S4  9   Table S5  10   Table S6  13 Suppl. AGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCG  GGAAGCGTGGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCAC  GAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCAC  TGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTAC  GGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCC  GGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGA  TCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAG  GATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTT  ACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGA  TAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTAT  CAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTT  GCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCT  CGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGG  TTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATT  CTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGC  GACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAAC  GTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTT  CAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACA  CGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATA  TTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCGACGGATCGGG  AGATCTCCCGATCCCCTATGGTCGACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGTATCTGCTCCCTGCTTGTG  TGTTGGAGGTCGCTGAGTAGTGCGCGAGCAAAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTG  CTTAGGGTTAGGCGTTTTGCGCTGCTTCGCGACAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGC  AGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTCCG  CGGTTAGTTTTTGTATTGGAAGGGCTGGTCGCCAGTCTCATTGAGAAGGCATGTGCGGACGATGGCTTCTGTCACTGCAAAGGG  GTCACAATTGGCAGAGGGGCGGCGGTCTTCAAAGTAACCTTTCTTCTCCTGGCCGACAGTCCGGGGAATGCGGATGCTGGCACT  GCGATTGGCGACACCAGCAGAAAAGTCGTTGATGTTGGACGTTTCGTGGAACCCAGTCAGACGACGGGCATTGTCCAGGCCCCC  CTTGGGATCGTAGGCTCGAATGTGGTACCGGTGCCGCTTGCTTAGTTTCTCGATGGCCTCCTCGATGTGCTTCAGACCATTCTC  CTCCCGCATGGCCTTGGTGCTAAAGTTGGTATGGCAGCCTGCACCATTCCAGTTCCCAGGAATGGGCTTGGGGTCAAAGGTTGC  TATTACCCCAAAGTCTTCACATACTCGATGCAAGATGAAACGGGCCACCCAGAGATGATCTCCCATGCGGATTCCTTCACAGGG  TCCTATTTGGAATTCCCACTGGGCAGGCATGACCTCAGCATTTGTTCCTGTAATCTTGACCCCAGCATACAAGCAGGCGCGGTA  GTGAGCCTCCACGATATCCCTGCCATAGGCTTTGTCTGCGCCCACACCACAGTAATACGGACCTTGGGGCCCAGGAAAGCCATT  GGAAGGCCAACCAAAAGGGTGCCCATCTGTTCCCATCAGAGTATACTCCTGTTCCATTCCAAACCAGGGGTGCTGGTTGCTCAC  CATGTCCATTATCCGTTTACACGAGTGCCTTAAATTGGTCTCTGCAGGCTTCCGGTTGTACTTGAAAACTTCACAGAACACCAG  CTTGTTGGGATCTCTGCGGAAGGGGTCCCGAAACATGGCAACAGGGCTGAGATACATGTCACTGTTGGAGCCCTCAGACTGAAA  GGTACTAGAGCCATCAAAATTCCACTCAGGTAACTCTTCTACACACTTGGGCTCACAGTCCAGGGTGCGGGTTTTGCAGCGCAG  TCCTTCTCCAGTACCATCAACCCAGATATACATGGCTTGGACTTTCTCACCCTGGGGCAGGCACAAGTACATTTGCTTGATGTT  TTTGTTCAAGTGGGAACTTGCTGAGGTGGCCATATCGATCGAAAATGGATATACAAGCTCCCGGGAGCTTTTTGCAAAAGCCTA  GGCCTCCAAAAAAGCCTCCTCACTACTTCTGGAATAGCTCAGAGGCAGAGGCGGCCTCGGCCTCTGCATAAATAAAAAAAATTA  GTCAGCCATGGGGCGGAGAATGGGCGGAACTGGGCGGAGTTAGGGGCGGGATGGGCGGAGTTAGGGGCGGGACTATGGTTGCT  GACTAATTGAGATGCATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCTGGTTGCTGACTAATTGAGA  TGCATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCCTAACTGACACACATTCCACAGACGTCGCTCGA  TGTACGGGCCAGATATACGCGTAGTCAATGGGAAAAACCCATTGGAGCCAAGTACACTGACTCAATAGGGACTTTCCATTGGGT  TTTGCCCAGTACATAAGGTCAATAGGGGGTGAGTCAACAGGAAAGTCCCATTGGAGCCAAGTACATTGAGTCAATAGGGACTT  TCCAATGGGTTTTGCCCAGTACATAAGGTCAATGGGAGGTAAGCCAATGGGTTTTTCCCATTACTGACATGTATACTGAGTCAT  TAGGGACTTTCCAATGGGTTTTGCCCAGTACATAAGGTCAATAGGGGTGAATCAACAGGAAAGTCCCATTGGAGCCAAGTACA  CTGAGTCAATAGGGACTTTCCATTGGGTTTTGCCCAGTACAAAAGGTCAATAGGGGGTGAGTCAATGGGTTTTTCCCATTATTG  GCACATACATAAGGTCAATAGGGGTGACTAGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGG  GTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCC  GAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTTGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGCTG  AAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGC  CGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGC  GCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTT  TCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACagtgcgatCGCCACCATGGCCAGCAGACTGACACTGCTGACCC  TGCTGCTCCTCCTGCTGGCTGGAGACAGGGCTTCCTCCAACCCCAACGCCACCAGCAGCAGCTCCCAGGACCCTGAGTCCCTCCA  GGACAGGGGAGAAGGCAAGGTCGCCACCACCGTCATCTCCAAAATGCTCTTCGTCGAGCCCATCCTCGAGGTCAGCTCCCTCCCC  ACCACAAACAGCACAACCAACAGCGCCACCAAGATCACCGCCAACACCACCGACGAACCCACAACCCAGCCCACCACAGAGCCTA  CAACACAGCCTACCATCCAGCCTACCCAACCCACCACCCAGCTCCCTACCGACTCCCCTACCCAGCCTACCACAGGCTCCTTTTGT  CCCGGACCTGTGACCCTGTGCTCCGACCTGGAGTCCCATAGCACAGAGGCTGTCCTCGGAGATGCCCTGGTGGATTTCAGCCTCA  AACTCTACCACGCCTTCAGCGCCATGAAGAAGGTCGAGACCAATATGGCCTTCTCCCCCTTTAGCATCGCCAGCCTGCTCACCCA  AGTCCTGCTCGGAGCCGGCGAGAATACCAAGACCAACCTGGAGAGCATCCTGTCCTACCCTAAGGACTTCACCTGCGTCCACCA  GGCCCTCAAGGGCTTTACCACCAAAGGAGTCACATCCGTCAGCCAGATCTTCCATTCCCCTGACCTCGCCATTAGGGACACATTC BGHpA mCMV-hEF-1a-5' promoter ST6GAL1   BGHpA   GTGAACGCCTCCAGGACCCTGTACAGCAGCTCCCCTAGGGTCCTGTCCAACAACAGCGACGCCAACCTGGAGCTCATTAATACA  TGGGTGGCCAAGAATACAAACAACAAGATTAGCAGGCTCCTGGATAGCCTGCCTTCCGACACCAGGCTCGTGCTCCTCAATGCC  ATCTACCTCTCCGCCAAGTGGAAGACCACATTCGACCCCAAGAAAACAAGGATGGAGCCCTTTCACTTTAAAAATAGCGTGATC  AAGGTGCCCATGATGAACAGCAAGAAGTACCCTGTCGCCCACTTCATCGACCAGACCCTGAAGGCTAAGGTGGGACAGCTCCAA  CTGTCCCATAATCTGAGCCTGGTCATCCTCGTGCCTCAGAACCTGAAGCACAGGCTGGAGGACATGGAACAGGCCCTGTCCCCC  AGCGTGTTTAAGGCCATCATGGAAAAACTCGAGATGTCCAAGTTTCAACCCACCCTCCTCACCCTGCCCAGAATTAAGGTCACC  ACAAGCCAGGACATGCTCAGCATTATGGAGAAGCTCGAGTTCTTCGATTTCTCCTACGACCTCAACCTCTGCGGCCTGACAGAA  GACCCTGACCTGCAGGTGAGCGCCATGCAGCACCAGACAGTGCTGGAGCTCACCGAGACAGGAGTGGAAGCTGCTGCCGCCTCC  GCTATTTCCGTGGCCAGGACCCTCCTGGTGTTCGAGGTGCAACAACCCTTCCTGTTCGTCCTGTGGGACCAACAACACAAGTTCC  CTGTGTTCATGGGCAGAGTCTACGACCCCAGAGCCTGAacacagtctCTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTC  CCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAG  TAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGG  ATGCGGTGGGCTCTATGGATTAAGCTCGCGTAGTCAATGGGAAAAACCCATTGGAGCCAAGTACACTGACTCAATAGGGACTT  TCCATTGGGTTTTGCCCAGTACATAAGGTCAATAGGGGGTGAGTCAACAGGAAAGTCCCATTGGAGCCAAGTACATTGAGTCA  ATAGGGACTTTCCAATGGGTTTTGCCCAGTACATAAGGTCAATGGGAGGTAAGCCAATGGGTTTTTCCCATTACTGACATGTAT  ACTGAGTCATTAGGGACTTTCCAATGGGTTTTGCCCAGTACATAAGGTCAATAGGGGTGAATCAACAGGAAAGTCCCATTGGA  GCCAAGTACACTGAGTCAATAGGGACTTTCCATTGGGTTTTGCCCAGTACAAAAGGTCAATAGGGGGTGAGTCAATGGGTTTT  TCCCATTATTGGCACATACATAAGGTCAATAGGGGTGACTAGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTT  GGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCC  GCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTTGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCA  GAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAG  TCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGC  CTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTGCTTGCTCAACTCTACGTCT  TTGTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACagtgcgatCGCCACCATGATCCACACCAACCT  GAAGAAGAAATTCTCCTGCTGCGTGCTGGTGTTCCTGCTGTTCGCCGTGATCTGCGTGTGGAAAGAGAAGAAGAAGGGCTCCTA  CTACGACTCCTTCAAGCTGCAGACCAAAGAATTCCAGGTGCTGAAGTCCCTGGGCAAGCTGGCCATGGGCTCCGACTCTCAGTC  CGTGTCCTCCAGCTCTACCCAGGACCCCCACAGAGGCAGACAGACCCTGGGCTCTCTGAGAGGCCTGGCCAAGGCTAAGCCTGA  GGCCTCCTTCCAGGTGTGGAACAAGGACTCCTCCAGCAAGAACCTGATCCCCCGGCTGCAGAAGATCTGGAAGAACTACCTGTC  CATGAACAAGTACAAGGTGTCCTACAAGGGCCCTGGCCCTGGCATCAAGTTCTCTGCCGAGGCCCTGAGATGCCACCTGAGGGA  CCATGTGAACGTGTCCATGGTGGAAGTGACCGACTTCCCATTCAACACCTCCGAGTGGGAGGGCTACCTGCCCAAAGAGTCCAT  CCGGACCAAGGCTGGCCCTTGGGGCAGATGTGCTGTGGTGTCCTCTGCCGGCTCCCTGAAGTCCTCTCAGCTGGGCAGAGAGAT  CGACGACCACGACGCCGTGCTGCGGTTTAATGGCGCCCCTACCGCCAACTTCCAGCAGGACGTGGGCACCAAGACCACCATCCGG  CTGATGAACTCCCAGCTCGTGACAACCGAGAAGCGGTTCCTGAAGGACTCCCTGTACAACGAGGGCATCCTGATCGTGTGGGAC  CCCTCCGTGTACCACTCCGACATCCCCAAGTGGTATCAGAACCCCGACTACAACTTCTTCAACAACTACAAGACCTACCGGAAGC  TGCACCCCAACCAGCCCTTCTACATCCTGAAGCCCCAGATGCCCTGGGAGCTGTGGGACATTCTGCAGGAAATCTCCCCCGAGGA  AATCCAGCCCAACCCCCCTTCCTCTGGCATGCTGGGCATCATTATCATGATGACCCTGTGCGACCAGGTGGACATCTACGAGTT  TCTGCCCTCCAAGAGAAAGACCGACGTGTGCTACTACTACCAGAAGTTCTTCGACTCCGCCTGCACCATGGGCGCCTACCACCCT  CTGCTGTACGAGAAGAACCTCGTGAAGCACCTGAACCAGGGCACCGACGAGGATATCTACCTGCTGGGCAAGGCCACCCTGCCT  GGCTTCAGAACCATCCACTGCTGAacacagtctCTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCT  TGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTA  TTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCT  ATGG   A1AT  plasmid   AmpR   Bla   agacgtcaTGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCC  ATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACC  AGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCG  GGAAGCGTGGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCAC  GAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCAC  TGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTAC  GGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCC  GGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGA  TCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAG  GATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTT  ACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGA  TAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTAT  CAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTT  GCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCT  CGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGG  TTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATT  CTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGC  GACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAAC  GTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTT  CAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACA  CGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATA  TTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCGACGGATCGGG  promoter   SV40pA   GLUL   SV40  promoter mCMV-hEF-1a-5' promoter A1AT BGHpA mCMV-hEF-1a-5' promoter AGATCTCCCGATCCCCTATGGTCGACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGTATCTGCTCCCTGCTTGTG  TGTTGGAGGTCGCTGAGTAGTGCGCGAGCAAAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTG  CTTAGGGTTAGGCGTTTTGCGCTGCTTCGCGACAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAATGC  AGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTCCG  CGGTTAGTTTTTGTATTGGAAGGGCTGGTCGCCAGTCTCATTGAGAAGGCATGTGCGGACGATGGCTTCTGTCACTGCAAAGGG  GTCACAATTGGCAGAGGGGCGGCGGTCTTCAAAGTAACCTTTCTTCTCCTGGCCGACAGTCCGGGGAATGCGGATGCTGGCACT  GCGATTGGCGACACCAGCAGAAAAGTCGTTGATGTTGGACGTTTCGTGGAACCCAGTCAGACGACGGGCATTGTCCAGGCCCCC  CTTGGGATCGTAGGCTCGAATGTGGTACCGGTGCCGCTTGCTTAGTTTCTCGATGGCCTCCTCGATGTGCTTCAGACCATTCTC  CTCCCGCATGGCCTTGGTGCTAAAGTTGGTATGGCAGCCTGCACCATTCCAGTTCCCAGGAATGGGCTTGGGGTCAAAGGTTGC  TATTACCCCAAAGTCTTCACATACTCGATGCAAGATGAAACGGGCCACCCAGAGATGATCTCCCATGCGGATTCCTTCACAGGG  TCCTATTTGGAATTCCCACTGGGCAGGCATGACCTCAGCATTTGTTCCTGTAATCTTGACCCCAGCATACAAGCAGGCGCGGTA  GTGAGCCTCCACGATATCCCTGCCATAGGCTTTGTCTGCGCCCACACCACAGTAATACGGACCTTGGGGCCCAGGAAAGCCATT  GGAAGGCCAACCAAAAGGGTGCCCATCTGTTCCCATCAGAGTATACTCCTGTTCCATTCCAAACCAGGGGTGCTGGTTGCTCAC  CATGTCCATTATCCGTTTACACGAGTGCCTTAAATTGGTCTCTGCAGGCTTCCGGTTGTACTTGAAAACTTCACAGAACACCAG  CTTGTTGGGATCTCTGCGGAAGGGGTCCCGAAACATGGCAACAGGGCTGAGATACATGTCACTGTTGGAGCCCTCAGACTGAAA  GGTACTAGAGCCATCAAAATTCCACTCAGGTAACTCTTCTACACACTTGGGCTCACAGTCCAGGGTGCGGGTTTTGCAGCGCAG  TCCTTCTCCAGTACCATCAACCCAGATATACATGGCTTGGACTTTCTCACCCTGGGGCAGGCACAAGTACATTTGCTTGATGTT  TTTGTTCAAGTGGGAACTTGCTGAGGTGGCCATATCGATCGAAAATGGATATACAAGCTCCCGGGAGCTTTTTGCAAAAGCCTA  GGCCTCCAAAAAAGCCTCCTCACTACTTCTGGAATAGCTCAGAGGCAGAGGCGGCCTCGGCCTCTGCATAAATAAAAAAAATTA  GTCAGCCATGGGGCGGAGAATGGGCGGAACTGGGCGGAGTTAGGGGCGGGATGGGCGGAGTTAGGGGCGGGACTATGGTTGCT  GACTAATTGAGATGCATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCTGGTTGCTGACTAATTGAGA  TGCATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCCTAACTGACACACATTCCACAGACGTCGCTCGA  TGTACGGGCCAGATATACGCGTAGTCAATGGGAAAAACCCATTGGAGCCAAGTACACTGACTCAATAGGGACTTTCCATTGGGT  TTTGCCCAGTACATAAGGTCAATAGGGGGTGAGTCAACAGGAAAGTCCCATTGGAGCCAAGTACATTGAGTCAATAGGGACTT  TCCAATGGGTTTTGCCCAGTACATAAGGTCAATGGGAGGTAAGCCAATGGGTTTTTCCCATTACTGACATGTATACTGAGTCAT  TAGGGACTTTCCAATGGGTTTTGCCCAGTACATAAGGTCAATAGGGGTGAATCAACAGGAAAGTCCCATTGGAGCCAAGTACA  CTGAGTCAATAGGGACTTTCCATTGGGTTTTGCCCAGTACAAAAGGTCAATAGGGGGTGAGTCAATGGGTTTTTCCCATTATTG  GCACATACATAAGGTCAATAGGGGTGACTAGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGG  GTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCC  GAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTTGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGCTG  AAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGC  CGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGC  GCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTT  TCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACagtgcgatCGCCACCATGCCCAGCTCCGTGAGCTGGGGCATTC  TCCTCCTCGCTGGCCTGTGCTGTCTGGTGCCTGTGAGCCTGGCCGAAGACCCCCAAGGAGACGCTGCTCAGAAGACAGACACAT  CCCACCATGACCAGGACCACCCCACCTTCAATAAGATCACCCCTAACCTCGCTGAGTTTGCCTTTTCCCTCTACAGGCAACTGGC  CCACCAGAGCAACTCCACCAATATCTTCTTTAGCCCTGTGAGCATCGCCACAGCCTTCGCCATGCTGAGCCTGGGCACCAAGGCT  GATACACATGACGAGATCCTGGAAGGACTGAACTTCAACCTGACCGAGATCCCCGAGGCCCAGATCCACGAGGGCTTCCAGGAA  CTGCTGAGGACCCTGAACCAGCCTGACAGCCAGCTCCAGCTCACCACCGGCAATGGCCTCTTCCTGAGCGAGGGCCTCAAGCTCG  TGGATAAGTTCCTGGAAGACGTGAAGAAGCTGTACCACTCCGAAGCCTTCACAGTGAACTTTGGCGACACAGAGGAGGCCAAG  AAGCAGATCAACGACTATGTGGAGAAGGGCACCCAGGGCAAGATCGTGGACCTCGTGAAGGAGCTGGATAGGGACACCGTGTT  CGCTCTCGTGAACTATATCTTCTTCAAGGGCAAGTGGGAGAGGCCCTTCGAGGTGAAAGACACAGAGGAAGAGGACTTCCACGT  CGACCAAGTGACCACAGTCAAGGTCCCCATGATGAAGAGACTGGGCATGTTCAACATCCAGCATTGCAAAAAGCTGAGCAGCTG  GGTGCTGCTCATGAAGTATCTCGGCAACGCCACAGCCATCTTCTTCCTGCCCGATGAGGGCAAGCTCCAGCATCTGGAAAACGA  GCTCACCCACGACATTATCACCAAGTTTCTGGAGAACGAAGACAGGAGGAGCGCTAGCCTCCACCTCCCCAAACTCAGCATCAC  CGGCACATATGACCTGAAGTCCGTCCTCGGCCAGCTGGGCATCACAAAGGTCTTCTCCAACGGCGCCGACCTGAGCGGAGTCAC  AGAAGAGGCTCCCCTGAAGCTGAGCAAGGCTGTGCATAAGGCCGTGCTGACAATTGACGAGAAAGGCACAGAGGCTGCCGGAG  CCATGTTCCTGGAAGCTATCCCCATGAGCATCCCCCCCGAGGTGAAATTCAACAAACCCTTCGTGTTCCTGATGATCGAGCAGA  ACACCAAGTCCCCCCTCTTCATGGGCAAGGTCGTGAACCCCACCCAGAAGTAAacacagtctCTGTGCCTTCTAGTTGCCAGCCATC  TGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCA  TCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAG  CAGGCATGCTGGGGATGCGGTGGGCTCTATGGATTAAGCTCGCGTAGTCAATGGGAAAAACCCATTGGAGCCAAGTACACTGAC  TCAATAGGGACTTTCCATTGGGTTTTGCCCAGTACATAAGGTCAATAGGGGGTGAGTCAACAGGAAAGTCCCATTGGAGCCAA  GTACATTGAGTCAATAGGGACTTTCCAATGGGTTTTGCCCAGTACATAAGGTCAATGGGAGGTAAGCCAATGGGTTTTTCCCAT  TACTGACATGTATACTGAGTCATTAGGGACTTTCCAATGGGTTTTGCCCAGTACATAAGGTCAATAGGGGTGAATCAACAGGA  AAGTCCCATTGGAGCCAAGTACACTGAGTCAATAGGGACTTTCCATTGGGTTTTGCCCAGTACAAAAGGTCAATAGGGGGTGA  GTCAATGGGTTTTTCCCATTATTGGCACATACATAAGGTCAATAGGGGTGACTAGTCAGTGGGCAGAGCGCACATCGCCCACAG  TCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTC  GTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTTGCCGTGAACGTTCTTTTTCGCAAC  GGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCATC  CACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAG  GTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTGCTTGCT  CAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACagtgcgatCGCCACCATGA  TCCACACCAACCTGAAGAAGAAATTCTCCTGCTGCGTGCTGGTGTTCCTGCTGTTCGCCGTGATCTGCGTGTGGAAAGAGAAGA  AGAAGGGCTCCTACTACGACTCCTTCAAGCTGCAGACCAAAGAATTCCAGGTGCTGAAGTCCCTGGGCAAGCTGGCCATGGGCT  CCGACTCTCAGTCCGTGTCCTCCAGCTCTACCCAGGACCCCCACAGAGGCAGACAGACCCTGGGCTCTCTGAGAGGCCTGGCCAA  GGCTAAGCCTGAGGCCTCCTTCCAGGTGTGGAACAAGGACTCCTCCAGCAAGAACCTGATCCCCCGGCTGCAGAAGATCTGGAA  GAACTACCTGTCCATGAACAAGTACAAGGTGTCCTACAAGGGCCCTGGCCCTGGCATCAAGTTCTCTGCCGAGGCCCTGAGATG  CCACCTGAGGGACCATGTGAACGTGTCCATGGTGGAAGTGACCGACTTCCCATTCAACACCTCCGAGTGGGAGGGCTACCTGCC  CAAAGAGTCCATCCGGACCAAGGCTGGCCCTTGGGGCAGATGTGCTGTGGTGTCCTCTGCCGGCTCCCTGAAGTCCTCTCAGCT 
